Tenofovir gel reduces risk for genital herpes simplex
Pericoital application of tenofovir gel, previously studied for HIV, linked to reduced risk of herpes infection.
Pericoital application of tenofovir gel, previously studied for HIV, linked to reduced risk of herpes infection.
Valacyclovir reduced HIV-1 levels in patients who did not have the herpes simplex virus 2.
Despite a less-than-robust efficacy profile, lysine supplementation is a safe and inexpensive remedy to try in patients with recurrent HSV outbreaks.
A patient, aged 65 years, presented with complaints of an itchy rash in her groin. The patient had hypertension and hyperlipidemia and was prescribed several medications including atorvastatin and amlodipine. The patient reported that she was married with three grown children.
There were marked increases in the prevalence of HIV from 7% to 13% for nearly all demographic subgroups in two cohorts of noninjection drug users.
Oral tenofovir-based prophylaxis for HIV also reduced herpes simplex virus-2 transmission.
Dose-dependent reduction seen in rate of genital HSV shedding and days with lesions.
Herpes simplex virus reactivation likely accounts for disease transmission during therapy, prompting researchers to call for new treatments to successfully control and prevent onward HSV transmission.
A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general population of uninfected women.
Xerese is indicated for the early treatment of recurrent herpes labialis, to reduce the likelihood of ulcerative cold sores and to shorten the lesion-healing time in adults and adolescents.